Intuitive Surgical CMO exercises 105 options, sells 105 at $560

Intuitive Surgical (ISRG) executive transaction: EVP & Chief Medical Officer Myriam Curet exercised 105 stock options at $229.39 and, on the same day (11/10/2025), sold 105 common shares at $560 under a Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Intuitive Surgical (ISRG) executive transaction: EVP & Chief Medical Officer Myriam Curet exercised 105 stock options at $229.39 and, on the same day (11/10/2025), sold 105 common shares at $560 under a Rule 10b5-1 trading plan.

Following these transactions, she reported 0 shares held directly, 353 shares held indirectly by a trust, and 1,571 non-qualified stock options remaining outstanding (expiration 02/27/2030).

Insider Trade Summary

Exercise and Sale: 105 shares ($35K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Curet Myriam

Role EVP & Chief Medical Officer

Sold 105 shs ($59K)

Approx. gross sale proceeds $59K

Approx. exercise cost $24K

Approx. pre-tax spread $35K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right to buy)	105	$0.00	$0.00
Exercise	Common Stock	105	$229.39	$24K
Sale	Common Stock	105	$560.00	$59K
holding	Common Stock	--	--	--

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 1,571 contracts (Direct); Common Stock — 0 shares (Direct); Common Stock — 353 shares (Indirect, by Trust)

Footnotes (2)

1. F1. The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.
2. F2. 12.5% of the shares subject to the option vest on the six-month anniversary measured from February 10, 2023, and 1/48th of the total number of shares vest in forty-two (42) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ISRG’s CMO report on Form 4?

She exercised 105 options at $229.39 and sold 105 shares at $560 on 11/10/2025 under a Rule 10b5-1 plan.

Was the ISRG insider trade under a 10b5-1 plan?

Yes. The filing states the transactions were executed under a Rule 10b5-1 trading plan.

How many ISRG shares does the reporting person now own?

Direct common shares reported were 0; 353 shares are held indirectly by a trust.

What options remain after the ISRG transaction?

She reported 1,571 non-qualified stock options outstanding, expiring on 02/27/2030.

What is the role of the reporting person at ISRG?

She is an Officer, serving as EVP & Chief Medical Officer.

What were the transaction codes on the Form 4?

Code M for option exercise and code S for sale, both on 11/10/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 02:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Curet Myriam

(Last) (First) (Middle)

1020 KIFER ROAD

(Street)

SUNNYVALE CA 94086

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTUITIVE SURGICAL INC [ ISRG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2025		M(1)		105	A	$229.39	105	D
Common Stock	11/10/2025		S(1)		105	D	$560	0	D
Common Stock								353	I	by Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$229.39	11/10/2025		M(1)			105	(2)	02/27/2030	Common Stock	105	$0.0	1,571	D

Explanation of Responses:

1. The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

2. 12.5% of the shares subject to the option vest on the six-month anniversary measured from February 10, 2023, and 1/48th of the total number of shares vest in forty-two (42) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

	By: Stephanie Lim-Ignacio For: McAdams, Myriam Curet	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.